Insurance coverage for weight loss injections depends on your specific plan, your BMI, and any related health conditions you have. Three FDA-approved injectable medications are currently used for chronic weight management: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). Whether your plan covers any of them varies widely, and even plans that do cover them typically require prior authorization and documented proof that you meet specific criteria.
The Three Main Weight Loss Injections
Wegovy and Zepbound are the two most commonly prescribed weight loss shots today. Wegovy is a once-weekly injection that mimics a gut hormone called GLP-1 to reduce appetite and food intake. Zepbound is also a once-weekly injection, but it mimics two hormones (GLP-1 and GIP), which may give it a slight edge in total weight loss for some patients. Saxenda, the oldest of the three, is a daily injection that works through the same GLP-1 pathway as Wegovy but at a lower dose of a different drug.
All three are FDA-approved specifically for chronic weight management, meaning they’re intended for long-term use alongside a reduced-calorie diet and increased physical activity. This distinction matters because a related drug, Ozempic, contains the same active ingredient as Wegovy but is only approved for type 2 diabetes. Insurance will generally not cover Ozempic when prescribed purely for weight loss, since that’s considered off-label use.
What Insurance Companies Require for Coverage
Even when a plan includes weight loss injections on its formulary, you’ll almost certainly face a prior authorization process. Your doctor needs to submit documentation proving you meet the plan’s criteria. While the specifics vary by insurer, the standard thresholds are consistent across most plans:
- BMI of 30 or higher, or
- BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol
Many plans also require that you’ve already tried to lose weight through other means before they’ll approve an injectable. Some insurers, like the State Health Plan of North Carolina, require participation in a comprehensive weight management program (including behavioral counseling, a reduced-calorie diet, and increased physical activity) for at least six months before drug therapy is authorized. Others may require you to try a less expensive oral medication first, a process called step therapy.
Once you’re approved, continued coverage isn’t guaranteed. Plans commonly require you to show that the medication is working after three months at a stable dose. A typical benchmark is losing at least 5% of your starting body weight. If you don’t hit that target, coverage can be denied for refills.
How Employer Plans Differ
If you get insurance through your employer, coverage for weight loss medications is not a given. Many employer-sponsored plans specifically exclude anti-obesity drugs, and whether yours includes them often depends on how large your company is.
According to KFF data from 2025, only 19% of firms with 200 or more workers cover GLP-1 drugs for weight loss in their largest health plan. The numbers rise with company size: 16% of firms with 200 to 999 employees offer coverage, 30% of firms with 1,000 to 4,999 employees, and 43% of firms with 5,000 or more employees. So if you work for a very large company, your odds are meaningfully better, but even then it’s far from universal.
The simplest way to check is to call the number on the back of your insurance card and ask whether Wegovy or Zepbound is on your plan’s formulary. If it is, ask about prior authorization requirements and any step therapy rules so your doctor knows exactly what to document.
Medicare Coverage
Medicare has historically excluded drugs used solely for weight loss from Part D coverage. That exclusion still technically exists, but there are two important exceptions.
First, if you have established cardiovascular disease along with obesity or overweight, Medicare Part D already covers Wegovy. This became possible in March 2024 when the FDA approved Wegovy specifically to reduce the risk of major cardiovascular events like heart attacks and strokes. Similarly, Zepbound has been approved for obstructive sleep apnea in adults with obesity, which gives it a separate covered pathway. In both cases, the coverage is tied to the non-obesity indication, not to weight loss itself.
Second, starting July 1, 2026, CMS is launching a short-term pilot program called the Medicare GLP-1 Bridge. This demonstration will run through December 31, 2027, and will provide eligible Part D beneficiaries with access to GLP-1 weight loss drugs under specific criteria. Qualifying requires a BMI of at least 35, or a BMI of 30 or higher with certain conditions like heart failure, uncontrolled high blood pressure, or stage 3a chronic kidney disease, or a BMI of 27 or higher with pre-diabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease. If you’re on Medicare and interested, talk to your doctor about whether you’d qualify once the program begins.
Medicaid Coverage
Medicaid coverage for weight loss injections varies dramatically by state. Some state Medicaid programs cover anti-obesity medications, while many others exclude them entirely. There’s no federal mandate requiring Medicaid to include these drugs. Your best option is to contact your state’s Medicaid office directly or check your plan’s drug formulary online.
What You’ll Pay Out of Pocket
Without any insurance coverage, weight loss injections can cost over $1,000 per month at retail prices. Even with coverage, your copay depends on which formulary tier the drug falls on. Most plans that do cover these medications place them on specialty or non-preferred brand tiers, meaning higher cost-sharing for you.
If your insurance doesn’t cover the medication at all, manufacturer savings programs can reduce the cost significantly. Zepbound’s savings card, for example, brings the price down to as low as $499 per month for the standard single-dose pen for patients with commercial insurance that doesn’t cover it. Lower doses of the multi-dose pen version start at $299 per month. These savings cards are available through the end of 2026 and are limited to 13 fills per calendar year. You must have commercial insurance to qualify, so Medicare, Medicaid, and other government program beneficiaries are not eligible.
Wegovy and Saxenda have their own manufacturer programs with similar structures. It’s worth checking the manufacturer’s website for each drug, since these programs change frequently and new options appear regularly.
How to Improve Your Chances of Approval
The prior authorization process can feel like a bureaucratic obstacle course, but a few practical steps make approval more likely. Before your doctor submits the request, make sure your medical record includes a documented BMI that meets the threshold, a list of weight-related conditions you’ve been diagnosed with, and evidence of previous weight loss attempts (whether that’s records from a dietitian, a gym membership, or notes from prior visits discussing diet and exercise). Some plans want to see that you’ve tried an oral weight loss medication or a structured program first, so having that history on file saves time.
If your prior authorization is denied, you have the right to appeal. Your doctor can submit additional documentation, such as lab results showing worsening metabolic health or a letter of medical necessity explaining why the injectable is appropriate for your situation. Many denials are overturned on appeal, particularly when the initial submission was missing a piece of required documentation rather than reflecting a true policy exclusion.